{
    "clinical_study": {
        "@rank": "48551", 
        "acronym": "ILLUMENATE Piv", 
        "arm_group": [
            {
                "arm_group_label": "Bare PTA", 
                "arm_group_type": "Active Comparator", 
                "description": "The control device is a CE-marked, commercially available PTA balloon catheter (EverCross\u2122 0.035 PTA Balloon Catheter, Covidien/ev3\u00ae Incorporated, Plymouth, MN 55441, USA)."
            }, 
            {
                "arm_group_label": "drug-coated PTA", 
                "arm_group_type": "Experimental", 
                "description": "The CVI Paclitaxel-coated PTA Catheter (CV Ingenuity Corporation/Covidien, Fremont, CA, 94555 USA) is a CE-marked, commercially available PTA balloon catheter (EverCross\u00ae 0.035\" PTA Balloon Catheter, Covidien/ev3\u00ae, Plymouth, MN 55441, USA) coated with paclitaxel using a proprietary carrier."
            }
        ], 
        "brief_summary": {
            "textblock": "This study is designed to demonstrate safety and efficacy of a Paclitaxel-coated\n      percutaneous transluminal angioplasty (PTA) Catheter to treat peripheral arterial disease.\n      There are two hypotheses being tested. 1) The drug-coated PTA catheter is as safe as the PTA\n      catheter without drug and 2)The drug-coated PTA catheter is more effective than the catheter\n      without drug."
        }, 
        "brief_title": "ILLUMENATE Pivotal, CVI Drug-coated Balloon vs. Uncoated Balloon", 
        "condition": "Peripheral Artery Disease", 
        "condition_browse": {
            "mesh_term": "Peripheral Arterial Disease"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subjects with symptomatic leg ischemia, requiring treatment of the Superficial\n             Femoral Artery (SFA) or popliteal artery.\n\n        Exclusion Criteria:\n\n          -  Known intolerance to study medications, paclitaxel or contrast agents that in the\n             opinion of the investigator cannot be adequately pre-treated"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "360", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 8, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01858428", 
            "org_study_id": "TP-1397"
        }, 
        "intervention": [
            {
                "arm_group_label": "drug-coated PTA", 
                "intervention_name": "Cardiovascular Ingenuity (CVI) Paclitaxel-coated Percutaneous Transluminal Angioplasty Balloon Catheter", 
                "intervention_type": "Device"
            }, 
            {
                "arm_group_label": "Bare PTA", 
                "intervention_name": "EverCross Percutaneous Transluminal Balloon Catheter", 
                "intervention_type": "Device"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Paclitaxel"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "February 12, 2014", 
        "location": {
            "contact": {
                "last_name": "Matheen Khuddus, MD", 
                "phone": "352-331-8570"
            }, 
            "facility": {
                "address": {
                    "city": "Gainesville", 
                    "country": "United States", 
                    "state": "Florida", 
                    "zip": "32605"
                }, 
                "name": "The Cardiac and Vascular Institute"
            }, 
            "investigator": [
                {
                    "last_name": "Matheen Khuddus, MD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Arthur Lee, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Daniel Van Roy, MD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "ProspectIve, Randomized, SingLe-Blind, U.S. MuLti-Center Study to EvalUate TreatMent of Obstructive SupErficial Femoral Artery or Popliteal LesioNs With A Novel PacliTaxel-CoatEd Percutaneous Angioplasty Balloon", 
        "overall_official": [
            {
                "affiliation": "Mt. Sinai Medical Center", 
                "last_name": "Prakash Krishnan, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "The Cleveland Clinic", 
                "last_name": "Sean Lyden, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Patency at 12 months post-procedure.  Patency is defined as the absence of target lesion restenosis as determined by Duplex Ultrasound (Peak Systolic Velocity Ratio (PSVR) \u2264 2.5) and freedom from clinically-driven target lesion revascularization.", 
                "measure": "Patency at 12 months", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "description": "Freedom from device and procedure-related death through 30 days post-procedure and freedom from target limb major amputation and clinically-driven target lesion revascularization through 12 months post-procedure.", 
                "measure": "Freedom from device and procedure-related death through 30 days, TLR 12 months post procedure.", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01858428"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Covidien", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Covidien", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}